Geode Capital Management
BEAM icon

Geode Capital Management’s Beam Therapeutics BEAM Stock Holding History

Geode Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.1M Buy
2,596,963
+178,371
+7% +$5.39M ﹤0.01% 1283
2026
Q1 		$57.6M Buy
2,418,592
+66,684
+3% +$1.85M ﹤0.01% 1417
2025
Q4 		$65.2M Sell
2,351,908
-39,035
-2% -$996K ﹤0.01% 1337
2025
Q3 		$58M Buy
2,390,943
+136,682
+6% +$2.72M ﹤0.01% 1383
2025
Q2 		$38.3M Buy
2,254,261
+54,806
+2% +$954K ﹤0.01% 1570
2025
Q1 		$43M Buy
2,199,455
+395,081
+22% +$10.3M ﹤0.01% 1465
2024
Q4 		$44.8M Sell
1,804,374
-3,309
-0.2% -$84.5K ﹤0.01% 1498
2024
Q3 		$44.3M Buy
1,807,683
+78,102
+5% +$2.02M ﹤0.01% 1500
2024
Q2 		$40.5M Buy
1,729,581
+92,859
+6% +$2.28M ﹤0.01% 1499
2024
Q1 		$54.1M Buy
1,636,722
+61,443
+4% +$1.91M 0.01% 1303
2023
Q4 		$42.9M Buy
1,575,279
+106,531
+7% +$2.65M ﹤0.01% 1445
2023
Q3 		$35.3M Buy
1,468,748
+144,573
+11% +$3.88M ﹤0.01% 1465
2023
Q2 		$42.3M Buy
1,324,175
+121,846
+10% +$3.95M 0.01% 1367
2023
Q1 		$36.8M Buy
1,202,329
+49,389
+4% +$1.95M ﹤0.01% 1398
2022
Q4 		$45.1M Buy
1,152,940
+48,465
+4% +$2.17M 0.01% 1222
2022
Q3 		$52.6M Buy
1,104,475
+137,252
+14% +$7.83M 0.01% 1048
2022
Q2 		$37.4M Buy
967,223
+105,529
+12% +$4.19M 0.01% 1313
2022
Q1 		$49.4M Buy
861,694
+13,105
+2% +$860K 0.01% 1259
2021
Q4 		$67.6M Buy
848,589
+25,695
+3% +$2.2M 0.01% 1077
2021
Q3 		$71.6M Buy
822,894
+137,620
+20% +$13.8M 0.01% 994
2021
Q2 		$88.2M Buy
685,274
+88,869
+15% +$7.08M 0.01% 870
2021
Q1 		$47.7M Buy
596,405
+65,440
+12% +$6.23M 0.01% 1276
2020
Q4 		$43.3M Buy
530,965
+86,275
+19% +$4.24M 0.01% 1206
2020
Q3 		$10.9M Buy
444,690
+234,161
+111% +$5.81M ﹤0.01% 1884
2020
Q2 		$5.89M Buy
210,529
+138,963
+194% +$2.99M ﹤0.01% 2237
2020
Q1 		$1.29M Buy
+71,566
New +$1.56M ﹤0.01% 2907

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Geode Capital Management's BEAM Position: Q2 2026 in Review

Geode Capital Management increased its Beam Therapeutics (BEAM) stake by 7.4% in Q2 2026, buying an estimated $5.39M and bringing the position to 2,596,963 shares worth $89.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1283.

Geode Capital Management first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Geode Capital Management held 2,596,963 shares of Beam Therapeutics worth $89.1M as of Q2 2026.
  • Geode Capital Management bought 178,371 Beam Therapeutics shares in Q2 2026, an estimated $5.39M.
  • Beam Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1283 holding.
  • Geode Capital Management first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.